1 withdrawn. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
| Phase 2 | 1 | Withdrawn 1 |
Follow ERW316: new trials by email Literature Review of ERW316 trials Research Report on ERW316
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors ERW316, Fulvestrant, Letrozole - Advanced HR+/HER2- Breast Cancer, Advanced CCNE1-amplified Solid Tumors | Phase 1 / Phase 2 | Withdrawn | Novartis Pharmaceuticals | 2026-06-30 | 2026-06-22 |
Breast Neoplasms (1) · Prostatic Neoplasms (1)
2025 (1)